Recent advances in antiviral agents: Antiviral drug discovery for hepatitis viruses

Current Pharmaceutical Design

Volumn 12, Issue 11, 2006, Pages 1371-1377

  Tanikawa, K ^a,b  

^a KURUME UNIVERSITY   (Japan)

^b Kurume Research Center   (Japan)

Author keywords

Anti hepatitis virus agent; HBV; HCV; HDV; Liver disease

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; BAY 41 4109; BETA INTERFERON; CILUPREVIR; CLEVUDINE; CONSENSUS INTERFERON; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HEPTAZYME; INTERFERON; ISIS 14803; LAMIVUDINE; LEVOVIRIN; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAMIDINE; RIBAVIRIN; RIBOZYME; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELBIVUDINE; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIDARABINE PHOSPHATE; VX 950;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BLOOD TRANSFUSION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG POTENCY; DRUG RESEARCH; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; DRUG URINE LEVEL; ERADICATION THERAPY; HEMOLYTIC ANEMIA; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOMODULATION; LIVER CIRRHOSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; VACCINATION; VERTICAL TRANSMISSION; VIRUS CARRIER; VIRUS DNA CELL DNA INTERACTION; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS MUTATION; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS RESISTANCE; DRUG DESIGN; DRUG EFFECT;

ANTIVIRAL AGENTS; DRUG DESIGN; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMANS;

EID: 33744995579     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776361165     Document Type: Review

References (43)

1. Davey S. State of the world's vaccines and immunization. Geneva: World Health Organization 1996; 76-82
2. WHO. Global surveillance and control of hepatitis C. J Viral Hepatitis 1999; 6:35-47.
3. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nature Med 1996; 2: 1104-8.
4. Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Gastroenterology 1997; 113: 1668-74.
5. Liaw YF, Sung JJY, Chow WC, Farell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
6. Omata M, Yokosuka O, Takano S, Kato N, Hosoda K, Imazeki F, et al. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 1991; 338: 914-5.
7. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata, M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131: 174-81.
8. Kaimori A, Kanto T, Limn CK, Komoda Y, Oki C, Inoue M, et al. Pseudotype hepatitis C virus enters immature myeloid dendritic cells through the interaction with lectin. Virology 2004; 324: 74-83.
9. Kanto T, Hayashi N, Takehara T, Tatsumi T, Kuzushita N, Ito A, et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infecteded individuals. 1999; 162: 5584-91.
10. + T lymphocytes after infection with hepatitis C virus. J Virol 2001; 75: 5550-8.
11. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366-75.
12. Jain SK, Pemberton PW, Smith A, McMahon RFT, Burrows PC, Aboutwerat A, et al. Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. J Hepatol 2002; 36: 805-11.
13. Dreher D, and Junod AF. Role of oxygen free radicals in cancer development. Eur J Cancer 1996; 32A: 30-8.
14. Tanikawa, K. Pathogenesis and treatment of hepatitis C virus-related liver diseases. Hepatobiliary Pancreat Dis Int 2004; 3: 17-20.
15. Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26: 1393-8.
16. Zeuzem S, Diego M, Gane E, Reddy R, Pockros P, Prati D, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724-32.
17. Michel ML, Pol S, Brechot C, Tiollais P. Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future. Vaccine 2001; 19: 2395-9.
18. Sherman KE, Sjogren M, Creagar RL, Damiano MA, Freeman S, Lewey S, et al. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology 1998; 27: 1128-35.
19. Yano H, Iemura A, Haramaki M, Ogasawara S, Takayama A, Akiba J, et al. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 1999; 29: 1708-17.
20. Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A, et al. Combined intraarterial 5-Fluorouracil and subcutaneous interferon-α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94: 435-42.
21. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized triaL Lancet 2001; 358: 958-65.
22. Heathcote EJL, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998; 27: 1136-43.
23. Chang CN, Skalski V, Zhou JH, and Cheng Y. Biochemical pharmacology of (+)- and (-)-2′, 3′-dideoxy-3′-thiacytidine as antihepatitis B virus agents. J Biol Chem 1992; 267: 22414-20.
24. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714-7.
25. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-90.
26. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a nov́el mutation in the HBV polymerase. Gastroenterology 2003; 125: 292-7.
27. Lai CL, Rosmawati M, Lao J, Vlierberghe HV, Anderson FH, Thomas N, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002; 123: 1831-8.
28. Tenny DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resestant to lamivudine. Antimicrob Agents Chemother 2004; 48: 3498-507.
29. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, and Naoumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118: 346-55.
30. Watson J. Prospects for hepatitis C virus therapeutics: Levovirin and viramidine as improved derivatives of ribavirin. Curr Opin Investig Drug 2002; 3: 680-3.
31. Gish RG, Leung NW, Wright TL, Trinh H, Lang W, Kessler HA, et al. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002; 46: 1734-40.
32. Lai CL, Lim SG, Brown NA, Zhou XJ, Lloyd DM, Lee YM, et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 2004; 40: 719-26.
33. Marcellin P, Mommeja-Marin H, Sackes SL, Lau GK, Sereni D, Bronowicki JP, et al. A phase II dose escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004; 40: 140-8.
34. Deres K, Schröder CH, Paessens A, Goldmann S, Hacker HJ, Weber O, et al. Inhibition of hpatitis B virus replication by drug-induced depletion of nucleocapsids. Science 2003; 299: 893-6.
35. McHutchison JG, and Patel K. Future therapy of hepatitis C. Hepatology 2002; 36: S245-52.
36. Lohmann V. Körner F, Koch JO, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-2.
37. Soler M, McHutchison JG, Kwoh TH, Dorr FA, Pawlotsky JM. Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment. Antivir Ther 2004, 9: 953-68.
38. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 186-9.
39. Lin C, Lin K, Luong YP, Rao BG, Wei YY, Brennan DL, et al. In vitro resistan e studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2004; 279: 17508-14.
40. Bordier BB, Ohkanda J, Liu P, Lee SY, Salazar FH, Marion PL, et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest 2003; 112: 407-14.
41. Brunetto MR, Bonino F. Treatment of chronic hepatitis B: from research to clinical practice via the consensus conferences. Curr Pharm Des 2004; 10(17): 2063-75.
42. Camma C, Di Bona D, Craxi A. The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach. Curr Pharm Des 2004; 10(17): 2123-30.
43. Fabris P, Barnes E, Tositti G, Giordani MT, Grasso A, De Lalla F. Therapy of chronic hepatitis C virus infection in HIV co-infected people. Curr Pharm Des 2004; 10(17): 2111-22.